Evidence review and recommendations for the implementation of genomics for antimicrobial resistance surveillance: reports from an international expert group.

Autor:	Baker KS; Department of Clinical Infection, Microbiology and Immunology, University of Liverpool, Liverpool, UK; Department of Genetics, University of Cambridge, Cambridge, UK. Electronic address: kb827@cam.ac.uk., Jauneikaite E; Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK; NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance Department of Infectious Disease, Imperial College London, Hammersmith Hospital, London, UK., Nunn JG; Infectious Disease Challenge Area, Wellcome Trust, London, UK., Midega JT; Drug Resistant Infections, Wellcome Trust, London, UK., Atun R; Harvard T H Chan School of Public Health, Harvard University, Boston, MA, USA., Holt KE; Department of Infection Biology, London School of Hygiene & Tropical Medicine, London, UK; Department of Infectious Diseases, Central Clinical School, Monash University, Melbourne, VIC, Australia., Walia K; Division of Epidemiology and Communicable Diseases, Indian Council of Medical Research, Ansarinagar, New Delhi, India., Howden BP; The Centre for Pathogen Genomics, Doherty Institute, The University of Melbourne, Melbourne, VIC, Australia., Tate H; Office of Research, US Food and Drug Administration Center for Veterinary Medicine, Laurel, MD, USA., Okeke IN; Department of Pharmaceutical Microbiology, Faculty of Pharmacy, University of Ibadan, Ibadan, Oyo State, Nigeria., Carattoli A; Department of Molecular Medicine, University of Rome La Sapienza, Rome, Italy., Hsu LY; Saw Swee Hock School of Public Health and Yong Loo Lin School of Medicine, National University of Singapore, Singapore., Hopkins KL; HCAI, Fungal, AMR, AMU, and Sepsis Division and Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, UK Health Security Agency, London, UK., Muloi DM; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK; Animal and Human Health Department, International Livestock Research Institute, Nairobi, Kenya., Wheeler NE; Institute of Microbiology and Infection, University of Birmingham, Birmingham, Edgbaston, UK., Aanensen DM; Centre for Genomic Pathogen Surveillance, Nuffield Department of Medicine, University of Oxford, Big Data Institute, Oxford, UK., Mason LCE; NIHR Health Protection Research Unit in Gastrointestinal Infections, Department of Clinical Infection, Microbiology, and Immunology, University of Liverpool, Liverpool, UK., Rodgus J; NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance Department of Infectious Disease, Imperial College London, Hammersmith Hospital, London, UK., Hendriksen RS; National Food Institute, Technical University of Denmark, Kongens Lyngby, Denmark., Essack SY; Antimicrobial Research Unit, University of KwaZulu-Natal, Durban, South Africa., Egyir B; Department of Bacteriology, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon-Accra, Ghana., Halpin AL; Division of Healthcare Quality Promotion, US Centers for Disease Control and Prevention, Atlanta, GA, USA., MacCannell DR; Office of Advanced Molecular Detection, US Centers for Disease Control and Prevention, Atlanta, GA, USA., Campos J; National Center of Genomics and Bioinformatics, ANLIS Malbran, Buenos Aires, Argentina., Srikantiah P; Global Health Division, Bill & Melinda Gates Foundation, Seattle, WA, USA., Feasey NA; Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK; Malawi Liverpool Wellcome Research Programme, Blantyre, Malawi., Peacock SJ; Department of Medicine, University of Cambridge, Cambridge, UK.
Jazyk:	angličtina
Zdroj:	The Lancet. Microbe [Lancet Microbe] 2023 Dec; Vol. 4 (12), pp. e1035-e1039. Date of Electronic Publication: 2023 Nov 14.
DOI:	10.1016/S2666-5247(23)00281-1
Abstrakt:	Nearly a century after the beginning of the antibiotic era, which has been associated with unparalleled improvements in human health and reductions in mortality associated with infection, the dwindling pipeline for new antibiotic classes coupled with the inevitable spread of antimicrobial resistance (AMR) poses a major global challenge. Historically, surveillance of bacteria with AMR typically relied on phenotypic analysis of isolates taken from infected individuals, which provides only a low-resolution view of the epidemiology behind an individual infection or wider outbreak. Recent years have seen increasing adoption of powerful new genomic technologies with the potential to revolutionise AMR surveillance by providing a high-resolution picture of the AMR profile of the bacteria causing infections and providing real-time actionable information for treating and preventing infection. However, many barriers remain to be overcome before genomic technologies can be adopted as a standard part of routine AMR surveillance around the world. Accordingly, the Surveillance and Epidemiology of Drug-resistant Infections Consortium convened an expert working group to assess the benefits and challenges of using genomics for AMR surveillance. In this Series, we detail these discussions and provide recommendations from the working group that can help to realise the massive potential benefits for genomics in surveillance of AMR. Competing Interests: Declaration of interests KSB reports funding from the Biotechnology and Biological Sciences Research Council and Medical Research Council and partial salary cover from Wellcome Trust and the UK Health Security Agency (UKHSA) over the course of this work. EJ had partial salary cover from Wellcome Trust over the course of this work. RA reports funding unrelated to this study from Novo Nordisk, Roche, Novartis, and UICC, and honoraria (unrelated to this study) from Merck & Co, Novartis, and F Hoffmann-La Roche. BE and INO report receiving funding from the UK Department of Health and Social Care: with a grant managed by the Fleming Fund and work performed under the auspices of the SEQAFRICA project. INO reports funding from the Bill & Melinda Gates Foundation, Joint Programming Initiative in Antimicrobial Resistance, Wellcome Trust, Grand Challenges Africa Award, and UK Medical Research Council, royalties for Genetics: Genes, Genomes and Evolution (Oxford University Press) and Divining Without Seeds and for Antimicrobial Resistance in Developing Countries (Springer), consulting fees from Wellcome Trust, and honoraria for Harvard University seminars and Peter Wildy Lecture Award 2023. LYH reports funding from Pfizer and honoraria from BioMerieux for a lecture in 2022. DMM reports funding from the British Society for Antimicrobial Chemotherapy. NEW reports funding from Nuclear Threat Initiative, Medical Research Council, Open Philantropy, and Shionogi as well as consulting fees from Nuclear Threat Initiative. DMA reports funding from the National Institute for Health and Care Research. NAF reports funding from the Bill & Melinda Gates Foundation, UK Research and Innovation, and National Institute for Health and Care Research. SJP is a member of the scientific advisory board of Next Gen Diagnostics and was supported by Illumina to attend the European Congress of Clinical Microbiology and Infectious Disease conference. All other authors declare no competing interests. (Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu